Peptide Initiative
Back to Survodutide

Clinical trials

Every registered trial of Survodutide

49 studies, 6 still enrolling.

Plain-Language Summary

Plain-language reading of the public trial registries.

In short

  • Survodutide has a real but limited body of human research.
  • 49 registered studies in total.
  • 6 are still enrolling people, so this is active research, not just history.

What kind of research

  • 49 studies actually gave the peptide to volunteers and measured what happened. This is the kind of study that can show whether something works.
  • About 17,065 people took part in those.

A registered trial is a plan, not a result. Registration means a study was declared in advance; it says nothing about whether the peptide worked, and a trial can be registered and then abandoned.

Filter

Showing 49 of 49 trials for Survodutide.

  • NCT07768813 Phase 1Not Yet Recruiting44 enrolled2026

    A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity

    Boehringer Ingelheim

    Healthy · Obesity

  • NCT07754461 Phase 3Recruiting600 enrolled2026

    A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Boehringer Ingelheim

    Type 2 Diabetes

  • NCT07407348 Phase 1Recruiting80 enrolled2026

    A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body

    Boehringer Ingelheim

    Healthy · Obesity · Overweight

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07413913 Phase 1Completed56 enrolled2026

    A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like Injector

    Boehringer Ingelheim

    Healthy · Obesity

  • NCT07206290 Phase 2Not Yet Recruiting120 enrolled2026

    Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease

    University Medical Center Groningen

    Chronic Kidney Disease

  • 2024-519614-30-00 Revoked56 enrolled2026

    1404-0015

    Boehringer Ingelheim International GmbH

    Healthy volunteer trial

  • NCT07221591 Phase 1Completed100 enrolled2025

    A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body

    Boehringer Ingelheim

    Healthy

  • 2025-522325-35-00 Revoked100 enrolled2025

    1404-0103

    Boehringer Ingelheim International GmbH

    Healthy volunteer trial

  • NCT07071974 Phase 1Completed16 enrolled2025

    A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body

    Boehringer Ingelheim

    Healthy

  • 2025-521419-37-00 Revoked16 enrolled2025

    1404-0099

    Boehringer Ingelheim International GmbH

    Healthy volunteer trial

  • NCT06745284 Phase 1Active Not Recruiting64 enrolled2025

    A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity

    Boehringer Ingelheim

    Obesity

  • NCT06772532 Phase 1Completed30 enrolled2025

    A Study in Healthy People to Compare How 3 Different Formulations of Survodutide Are Taken up in the Body

    Boehringer Ingelheim

    Healthy

  • 2024-516529-30-00 Revoked30 enrolled2025

    1404-0074

    Boehringer Ingelheim International GmbH

    Healthy volunteer trial

  • NCT06632457 Phase 3Recruiting1,590 enrolled2024

    LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    Boehringer Ingelheim

    Metabolic Dysfunction Associated Steatohepatitis

  • NCT06632444 Phase 3Recruiting1,800 enrolled2024

    LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

    Boehringer Ingelheim

    Metabolic Dysfunction Associated Steatohepatitis (MASH) · Liver Fibrosis

  • NCT06564441 Phase 1Completed34 enrolled2024

    A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity

    Boehringer Ingelheim

    Overweight · Obesity

  • NCT05202353 Phase 1Active Not Recruiting29 enrolled2024

    A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver

    Boehringer Ingelheim

    Obesity

  • 2024-515417-17-00 Temporarily Halted30 enrolled2024

    14040047

    Boehringer Ingelheim International GmbH

    No targeted indication. Male and female subjects with obesity.

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • 2024-512332-29-00 Revoked30 enrolled2024

    1404-0008

    Boehringer Ingelheim International GmbH

    Overweight, Obesity

  • NCT06492135 Phase 1Completed30 enrolled2024

    A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body

    Boehringer Ingelheim

    Overweight · Obesity

  • 2023-505303-23-00 Revoked16 enrolled2024

    1404-0056

    Boehringer Ingelheim International GmbH

    Obesity

  • NCT06352411 Phase 1Completed42 enrolled2024

    A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems

    Boehringer Ingelheim

    Healthy · Renal Impairment

  • 2023-508557-13-00 Revoked54 enrolled2024

    1404-0009

    Boehringer Ingelheim International GmbH

    Renal impairment (mild, moderate and severe), Healthy

  • NCT06352424 Phase 1Completed23 enrolled2024

    A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity

    Boehringer Ingelheim

    Obesity

  • 2023-506233-30-01 Revoked24 enrolled2024

    1458-0006

    Boehringer Ingelheim International GmbH

    Obesity

  • NCT06309992 Phase 3Completed218 enrolled2024

    A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)

    Boehringer Ingelheim

    Obesity · Non-Alcoholic SteatoHepatitis (NASH)

  • NCT06200467 Phase 1Completed110 enrolled2024

    A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity

    Boehringer Ingelheim

    Overweight · Obesity

  • NCT06214741 Phase 3Completed307 enrolled2024

    A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight

    Boehringer Ingelheim

    Obesity · Overweight

  • 2022-502529-17-00 Revoked130 enrolled2024

    1404-0038

    Boehringer Ingelheim International GmbH, Boehringer Ingelheim RCV GmbH & Co. KG

    Obesity

  • 2022-502531-18-00 Revoked248 enrolled2024

    1404-0041

    Boehringer Ingelheim International GmbH, Boehringer Ingelheim RCV GmbH & Co. KG, Boehringer Ingelheim Espana S.A.

    Obesity, Diabetes mellitus type II

  • NCT06176365 Phase 3Completed274 enrolled2024

    A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease

    Boehringer Ingelheim

    Obesity

  • 2022-502442-27-00 Revoked2,042 enrolled2024

    1404-0040

    Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A., Boehringer Ingelheim RCV GmbH & Co. KG

    Obesity

  • NCT05896384 Phase 1Completed32 enrolled2023

    A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood

    Boehringer Ingelheim

    Healthy

  • 2022-503146-53-00 Revoked24 enrolled2023

    1404-0014

    Boehringer Ingelheim International GmbH

    pharmacokinetic trial

  • NCT06066528 Phase 3Completed755 enrolled2023

    A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

    Boehringer Ingelheim

    Obesity · Diabetes Mellitus, Type 2

  • NCT06066515 Phase 3Completed726 enrolled2023

    A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

    Boehringer Ingelheim

    Obesity

  • NCT06077864 Phase 3Completed5,531 enrolled2023

    A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

    Boehringer Ingelheim

    Obesity

  • NCT05751226 Phase 1Completed88 enrolled2023

    A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906

    Boehringer Ingelheim

    Healthy · Obesity

  • NCT05421338 Phase 1Completed6 enrolled2022

    A Study in Healthy Men to Test How BI 456906 is Processed in the Body

    Boehringer Ingelheim

    Healthy

  • NCT05296733 Phase 1Completed82 enrolled2022

    A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906

    Boehringer Ingelheim

    Healthy · Liver Diseases · Obesity

  • NCT04771273 Phase 2Completed295 enrolled2021

    A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

    Boehringer Ingelheim

    Non-alcoholic Steatohepatitis (NASH)

  • NCT04667377 Phase 2Completed387 enrolled2021

    A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight

    Boehringer Ingelheim

    Obesity

  • NCT04384081 Phase 1Completed37 enrolled2020

    A Study to Test How Different Doses of BI 456906 Are Tolerated in Japanese Men With a Body Mass Index (BMI) Between 23 and 40 kg/m2

    Boehringer Ingelheim

    Healthy

  • NCT04153929 Phase 2Completed413 enrolled2020

    A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

  • NCT03591718 Phase 1Completed131 enrolled2018

    A Study to Test Different Doses of BI 456906 in Patients With Obesity

    Boehringer Ingelheim

    Obesity

  • NCT03175211 Phase 1Completed20 enrolled2017

    Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 456906 in Healthy Male Volunteers

    Boehringer Ingelheim

    Healthy

  • 2025-525068-13-00 Authorised, Not Started95 enrolled

    22774

    Universitair Medisch Centrum Groningen

    Chronic Kidney Disease

  • 2026-526307-30-00 Authorised, Not Started44 enrolled

    1404-0145

    Boehringer Ingelheim International GmbH

    Healthy

  • 2025-524135-39-00 Authorised, Not Started56 enrolled

    1404-0118

    Boehringer Ingelheim International GmbH

    Healthy volunteer trial

Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered in more than one registry is counted once. A study is listed when Survodutide is named as an intervention. A registered trial is a plan, not a result — registration says nothing about whether the peptide worked.